Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (vol 401, pg 1079, 2023)

被引:0
作者
Craig, T. J.
Reshef, A.
Li, H. H.
机构
关键词
D O I
10.1016/S0140-6736(23)00739-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1266 / 1266
页数:1
相关论文
共 1 条
[1]   Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].
Craig, Timothy J. ;
Reshef, Avner ;
Li, H. Henry ;
Jacobs, Joshua S. ;
Bernstein, Jonathan A. ;
Farkas, Henriette ;
Yang, William H. ;
Stroes, Erik S. G. ;
Ohsawa, Isao ;
Tachdjian, Raffi ;
Manning, Michael E. ;
Lumry, William R. ;
Saguer, Inmaculada Martinez ;
Aygoeren-Puersuen, Emel ;
Ritchie, Bruce ;
Sussman, Gordon L. ;
Anderson, John ;
Kawahata, Kimito ;
Suzuki, Yusuke ;
Staubach, Petra ;
Treudler, Regina ;
Feuersenger, Henrike ;
Glassman, Fiona ;
Jacobs, Iris ;
Magerl, Markus .
LANCET, 2023, 401 (10382) :1079-1090